

# CERTIFICATE OF MAILING

37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

January 23, 2002

Date

COPY OF PAPERS ORIGINALLY FILED

**PATENT** 

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

David J. Mangelsdorf Bethany A. Janowski

Serial No.: 09/603,131

Filed: June 23, 2000

For: NOVEL OXY-STEROL LIGANDS FOR

THE LXR RECEPTOR AND USES

THEREOF

Group Art Unit: 1646

iighlander

Examiner: Unknown

Atty. Dkt. No.: UTSD:578USC2/SLH

RECEIVED

## REQUEST FOR CORRECTED FILING RECEIPT

TECH CENTER 1600/2900

Commissioner for Patents Washington, D.C. 20231

Sir:

A corrected filing receipt is hereby requested in view of the error which appears in the original. For the convenience of the Patent and Trademark Office, attached is a photocopy of the original receipt on which the error has been noted in red.

There is an error in Bethany A. Janowski's name. Please delete "Janowshi" and insert --Janowski--. In support of this requested correction, Applicants attach hereto a copy of the inventors' Declaration.

No fee is believed to be due in connection with the filing of this document. However, should any fee under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to this document, the Commissioner is hereby authorized to deduct said fee from Fulbright & Jaworski Deposit Account No.: 50-1212/10020402/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L. Highlander Reg. No. 37,642

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

January 23, 2002



£


# UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspto.gov



**CONFIRMATION NO. 3524** 

SERIAL NUMB 09/603,131	ER	FILING DATE 06/23/2000 RULE	C	<b>LASS</b> 435	GROUP ART UNIT 1646		ATTORNEY DOCKET NO. UTSD:578USC2/RAN			
APPLICANTS  Bethany A. Janowski, Dallas, TX; David John Mangelsdorf, Ducanville, TX;  ** CONTINUING DATA ********************  THIS APPLICATION IS A CON OF 08/943,936 09/26/1997 ABN WHICH CLAIMS BENEFIT OF 60/026,796 09/27/1996  ** FOREIGN APPLICATIONS ************************************										
Foreign Priority claimed  35 USC 119 (a-d) conditions met  Verified and Acknowledged  yes  no  Met after  Allowance  Allowance  Examiner's Signature  Initials				STATE OR COUNTRY TX	SHEETS DRAWING 5		TO1 CLA 1	IMS	INDEPENDENT CLAIMS 3	
ADDRESS Richard A Nakasl Fulbright & Jawor 600 Congress Av Suite 2400 Austin ,TX 78701	ski Ll enue	_P								
TITLE Novel oxy-sterol I	igand	s for the LXR receptor	and use	s thereof				•		
	FEES: Authority has been given in Paper No to charge/credit DEPOSIT ACCOUNT No for following:				All Fees  1.16 Fees ( Filing )					
					NT	1.17 Fees ( Processing Ext. of time )				
						☐ 1.18 Fees ( Issue ) ☐ Other				
							☐ Credit			





## United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

www.uspta.gov

APPLICATION NUMBER

FILING DATE

GRP ART UNIT 1646

FIL FEE REC'D ATTY DOCKET NO DRAWINGS

TOT CLAIMS

IND CLAIMS

09/603.131 / 06/23/2000 /

345

UTSD:578USC2/RAN

Richard A Nakashima Fulbright & Jaworski LLP 600 Congress Avenue **Suite 2400** Austin, TX 78701



**FILING RECEIPT** 

OC00000005395202

Date Mailed: 09/13/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Janoush

Bethany A. Janowshi, Dallas, TX; David John Mangelsdorf, Ducanville, TX; V

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CON OF 08/943,936 09/26/1997 / WHICH CLAIMS BENEFIT OF 60/026,796 09/27/1996

TECH CENTER 1600/2900

Foreign Applications

If Required, Foreign Filing License Granted 09/13/2000

\*\* SMALL ENTITY \*\*

Title

Novel oxy-sterol ligands for the LXR receptor and uses thereof

**Preliminary Class** 

435

Data entry by : HARRISON, BRUCE

Team : OIPE

Date: 09/13/2000



# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

### PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- · The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231